TransMedics Group, Inc.
TMDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.24 | 2.74 | 2.18 | -0.32 |
| FCF Yield | -3.91% | -7.48% | -3.16% | -6.12% |
| EV / EBITDA | 32.22 | -348.92 | -58.38 | -14.22 |
| Quality | ||||
| ROIC | 4.98% | -4.13% | -12.35% | -35.34% |
| Gross Margin | 59.36% | 63.77% | 69.84% | 69.92% |
| Cash Conversion Ratio | 1.38 | 0.52 | 1.26 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 67.80% | 99.87% | 53.90% | 8.64% |
| Free Cash Flow Growth | 57.86% | -232.77% | -78.25% | -5.41% |
| Safety | ||||
| Net Debt / EBITDA | 2.60 | -15.73 | 4.61 | -0.47 |
| Interest Coverage | 2.60 | -2.66 | -8.44 | -10.18 |
| Efficiency | ||||
| Inventory Turnover | 3.85 | 1.98 | 1.37 | 0.61 |
| Cash Conversion Cycle | 154.54 | 227.47 | 331.39 | 400.69 |